amaranth

(redirected from Amarantus)
Also found in: Dictionary, Thesaurus, Encyclopedia.

am·a·ranth

, amaranthum (am'ă-ranth, am-ă-ran'thŭm), [C.I. 16185]
An azo dye; a soluble reddish-brown powder that turns magenta red in solution; used as a food, pharmaceutical, and cosmetic coloring agent, and occasionally in histology.
[G. amaranthon, a never-fading flower]

am·a·ranth

(am'ă-ranth)
A weed (Amaranthus) of widespread geographic distribution; some species are consumed as a foodstuff; its prolific ability to produce seed allows its use as a flour. Purported value both internally and externally (e.g., astringent).
Synonym(s): love-lies-bleeding, red cockscomb.
[G. amaranthon, a never-fading flower]
References in periodicals archive ?
The use of funds will be mutually agreed between Amarantus and SeD Biomed.
Commissiong, president and chief executive officer of Amarantus.
Amarantus published positive results from a Phase 2 initial proof-of-concept clinical study in February of 2015 in the journal Brain, and highlighted the publication of two independent peer-reviewed scientific publications describing the mechanism of action of eltoprazine for the treatment of PD LID in August of 2015 and December 2016.
Additionally, the companies have entered into a Letter of Intent for Amarantus to assist Anavex in planning the blood-based biomarker components of Anavex' next Phase III trial in Alzheimer's patients.
Generex said Tuesday it would license its RapidMistT technologies to Amarantus, a California biotechnology company, in a $10 million deal including Amarantus stock.
As the Company searches for its next partner, RBCC's biotech subsidiary Rainbow Biosciences remains close to a joint venture deal with Amarantus Bioscience, makers of exciting new diagnostic tools and therapies for neurological diseases such as Parkinson's.
6 June 2016 - US-based biotechnology company Amarantus Bioscience Holdings, Inc.
Affichem SA, AIT Austrian Institute of Technology GmbH, Almac Diagnostics Limited, Amarantus Bioscience Holdings, Inc.
Biotechnology company Amarantus Bioscience Holdings (OtherOTC:AMBS) revealed on Thursday that it has received Australian patent no.
Maximum control of amarantus was for treatment Foramsulfuron these results are supported [3-11-6].
The Company's biotech subsidiary, Rainbow Biosciences, is close to finalizing a joint venture with Amarantus to develop and market new therapies and treatments for both neurological diseases including Parkinson's and physical traumas such as brain injury.
Under the deal, Avant issued to Amarantus 80m shares of common stock of Avant Diagnostics, representing approximately 45% of Avant's post-merger common stock, and 10m additional shares of common stock upon achievement of certain sales milestones.